Astellas Pharma Global Development
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma Global Development sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Astellas Pharma Global Development: 168 sponsored US clinical trials, 19 recruiting.
Astellas Pharma Global Development sponsors 168 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 121 completed. 28 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 10 trials.
Top-decile sponsor footprint
Astellas Pharma Global Development ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
121 of 139 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 3 of 4
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
NCT02588261
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
NCT02528643
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441517
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
NCT02571816
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
NCT02421939
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
NCT02372578
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
NCT02380274
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
NCT02383368
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02236013
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
NCT02175433
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
NCT02091960
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02138747
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
NCT03047083
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
NCT02091999
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
NCT02057380
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
NCT02113813
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
NCT02194491
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects
NCT02141425
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
NCT02128321
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
NCT02128893
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
NCT02103426
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
NCT01974206
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
NCT01963052
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02014558
A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
NCT02111317
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
NCT01977651
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
NCT01877655
Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects
NCT01918995
Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin
NCT01959399
A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects
NCT01929577
A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects
NCT02059590
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
NCT01780844
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects
NCT01813448
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate
NCT01884636
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
NCT01884558
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
NCT00815516
Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects
NCT01813461
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
NCT01711814
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
NCT01705483
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin
NCT01635946
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
NCT01650194
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
NCT01565655
A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K
NCT01686217
A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate
NCT02052375
Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion
NCT01635972
Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects
NCT01657890
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
NCT01618669
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
NCT01660477
Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects
NCT01657825
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 105 |
| Phase 2 | 27 |
| Phase 3 | 22 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Astellas Pharma Global Development pipeline
19 recruiting of 168 indexed (11% open); 121 completed (72%).
Phase mix: 28 late (III/IV) vs 132 early (I/II) (early-phase heavy).
Top condition: Healthy Volunteers (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma Global Development: open-pipeline peers nationwide
Peers matched on 168 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma Global Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 11% open enrollment (± trial volume)
- St. Louis University · 11% recruiting · 107 trials
- University of Connecticut · 11% recruiting · 107 trials
- Children's Mercy Hospital Kansas City · 11% recruiting · 184 trials
- Albert Einstein College of Medicine · 11% recruiting · 175 trials
Related
What to do with this Astellas Pharma Global Development page
168 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma Global Development or any single study.
- 19 of Astellas Pharma Global Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Astellas Pharma Global Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma Global Development pipeline card: 168 registered trials from official public datasets.Report a data error.